Prescribing advice
The supply for GLP-1 RA has largely improved with all strengths and presentations of semaglutide and dulaglutide now available. New biosimilar liraglutide preparations are now available.
Prescribers should consider prescribing GLP-1 RAs for patients within their licensed indications and in line with the relevant NICE guidelines.
Patients concerned about their current treatment, or who have questions about accessing these medicines, should contact their prescriber in the first instance.
NICE guidance
Prescribing advice is available from the following key resources:
- Type 2 diabetes in adults: management (NICE guideline [NG28])
- Overweight and obesity management (NICE guideline [NG246])
- NICE’s technology appraisal guidance on tirzepatide [TA1026] for managing overweight and obesity
- NICE’s technology appraisal guidance on semaglutide [TA875] for managing overweight and obesity
- NICE’s technology appraisal guidance on liraglutide [TA664] for managing overweight and obesity
Further advice
Medicines Supply Tool
Latest information on supply issues, actions to take, alternatives to use, and expected resolution dates. Content provided by DHSC and MVA team, NHS England.
Update history
- Added information regarding biosimilar liraglutide preparations are now available.
- Updated as supply for GLP-1 RA has largely improved.
- Updated to reflect publication of the MSN on 18 March 2024.
- Ozempic 0.5mg solution for injection in pre-filled pen is out of stock.
- Rybelsus supply position clarified.
- Link to the updated NatPSA published 3 Jan 2024; link to NG28 updated and link to CG189 has been added.
- Shortage of Byetta 10micrograms/0.04mL solution for injection 1.2mL pre-filled pens added.
- Product details and link to further information added for Wegovy. Status changed from intermittent to limited availability for other GLP-1 RAs.
- Content updated to reflect the publication of the NatPSA and Saxenda supply issue added.
- Bydureon has been added to the exenatide section.
- Published